Psoriasis Longitudinal Assessment and Registry (PSOLAR)

ID#: NCT00508547

Age: 18 - 99 years

Gender: All

Healthy Subjects: No

Recruitment Status: Recruiting

Start Date: June 21, 2007

End Date: May 31, 2021

Contact Information:
Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions
Summary: The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis and psoriatic arthritis occurring together). The registry study will track the behavior of the disease in response to other therapies, such as other biologic drugs. The registry will also evaluate clinical outcomes; disease characteristics, including physician reported assessment of psoriatic arthritis (PsA); quality of life, and potential risks for patients who may receive standard therapies for psoriasis.

Inclusion Criteria:

- Have a diagnosis of psoriasis

- Are candidates for, or are currently receiving conventional systemic agents (eg, methotrexate, acitretin, cyclosporine or systemic psoralen drug in combination with Ultraviolet A light [PUVA]) or biologic therapy for psoriasis including those with chronic severe (extensive and/or disabling) plaque psoriasis who may be treated with infliximab or those with moderate to severe plaque psoriasis who may be treated with ustekinumab, guselkumab, or another biologic agent

- Ability to understand and sign an informed consent form

- Are willing to participate in regular follow-up visits

Exclusion Criteria:

- Refuse to consent or are unwilling to respond to request for a long term information within the required time frame

- Are participating or have already planned to participate in a clinical trial with non-marketed investigational agents or are participating in a Centocor-sponsored clinical trial with marketed agents